902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma

Autologous Stem Cell Transplant for HIV-Associated Lymphoma: A Systematic Review and Meta-Analysis

Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Impact of Health Literacy in Hematology Outpatients Receiving Oral Anticancer Drugs and Followed By the Oncoral Multidisciplinary City-Hospital Educational Follow-up

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Meeting Cancer Survivorship Needs in Hematological Malignancies Compared to Solid Malignancies: Experiences of a Primary Care-Based Survivorship Clinic

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Waldenstr?m Macroglobulinemia: A Retrospective Analysis of US Claims Data

Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Virtual Care Use for Patients with Hematologic Malignancies – a Natural Policy Experiment